Therapy for Previously Treated Advanced HER2-Negative Gastric/GEJ Cancers

SWOG 1815 trial evaluating the first-line nab-paclitaxel + gemcitabine/cisplatin in advanced biliary tract cancers, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director Christopher H. Lieu, MD Manish A. Shah, MD Released: January 19, 2023